FDA ap­proves GSK's BC­MA drug, mark­ing a rocky re­turn to can­cer for the British gi­ant

De­spite con­cerns on both safe­ty and ef­fi­ca­cy, the FDA ap­proved Glax­o­SmithK­line’s mul­ti­ple myelo­ma drug be­lan­tam­ab mafodotin, de­cid­ing that for the sick­est pa­tients the ben­e­fits out­weighed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER